{"id":739811,"date":"2023-03-14T08:09:34","date_gmt":"2023-03-14T12:09:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/"},"modified":"2023-03-14T08:09:34","modified_gmt":"2023-03-14T12:09:34","slug":"biovie-announces-registration-details-for-biovie-day-webinar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/","title":{"rendered":"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar"},"content":{"rendered":"<h2>\nVirtual Webinar to be held March 23, 2023, at 10:00am Eastern Time<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CARSON CITY, Nev., March  14, 2023  (GLOBE NEWSWIRE) &#8212; BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced registration details for <em>BioVie Day\u2014<\/em>a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time.\u00a0<\/p>\n<p align=\"justify\">\n        <em>BioVie Day<\/em> will feature a comprehensive overview of the Company\u2019s programs in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Epigenetics &amp; Longevity, and Liver Disease, including the following topics:<\/p>\n<ul>\n<li>Overview of chronic low-grade inflammation and its impact on disease pathology<\/li>\n<li>Updates on Alzheimer\u2019s, Parkinson\u2019s, Epigenetics &amp; Longevity, and Liver Disease clinical programs\u00a0<\/li>\n<li>Clinical and regulatory strategy<\/li>\n<li>Approach to partnerships and commercialization<\/li>\n<li>Social Impact<\/li>\n<\/ul>\n<p align=\"justify\">A live question and answer session will follow the leadership teams\u2019 formal presentations.<\/p>\n<p align=\"justify\">To register for <em>BioVie Day<\/em>, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gmsi6kDqLHAaxsH58PixE-9Sn9Vff_txPv5lMmqOEwXZZHOSCjJ2PN4r2GdSEWtBXWUVp5W7tgbmyzrS0zHiN5SZU7muEdJBv8acYG6LIgg=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BioVie<\/strong>\n      <\/p>\n<p align=\"justify\">BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company\u2019s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer\u2019s and Parkinson\u2019s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer&#8217;s disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the\u00a0<em>Clinical Trial in Alzheimer\u2019s Disease<\/em>\u00a0(CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer\u2019s. A Phase 2 study of NE3107 in Parkinson\u2019s disease (NCT05083260) has completed, and topline data released in December 2022, showed clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company\u2019s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2b study for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http:\/\/www.bioviepharma.com\/.<\/p>\n<p align=\"justify\">Forward-Looking Statements\u00a0<br \/><em>This press release contains forward-looking statements, which may be identified by words such as &#8220;expect,&#8221; &#8220;look forward to,&#8221; &#8220;anticipate&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;will,&#8221; &#8220;project&#8221; or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company&#8217;s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to\u202fcomplete our pre-clinical or clinical studies and to obtain approval for our product\u202fcandidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company&#8217;s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.\u00a0<\/em><\/p>\n<p>\n        <em>For Investor Relations Inquiries:<\/em>\n      <\/p>\n<p>Contact:\u00a0<br \/>Bruce Mackle\u00a0<br \/><em>Managing Director<\/em>\u00a0<br \/>LifeSci Advisors, LLC\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9TAKmF6Nr8mHhQPcaCZo1j3yDbg_IpcAqqJDg4-pU4Jq1wR14eUZjLvPw5ACu367Q8qMa57xSE_Jktb_1xAkhF2DibOfXg-HQqPTWWlKmoEdPf1qOtJXpv9zdIM_KUmMXX3qhU70pzoOHkZ8sMyQN-7g4h3V0L8r3MzQ6XYRgR89GyWTal0hClEBTT0fecoaleyP92rYUqJn50gGcWdtZvSwGDZaXrJGifwA9C3v6iK3B4hPHx_0NCnnSYQ8DtfLAjm88t80rYAnEQURfv5P0g870ahRKyQLWDfnCMYHPX0=\" rel=\"nofollow noopener\" target=\"_blank\"><u>bmackle@lifesciadvisors.com<\/u><\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjgxNDdhNDItNTgxZS00ZjA2LWFiY2EtOWFlYTM4MzgyYTUwLTUwMDA3OTY2Ng==\/tiny\/BioVie-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) &#8212; BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced registration details for BioVie Day\u2014a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time.\u00a0 BioVie Day will feature a comprehensive overview of the Company\u2019s programs in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Epigenetics &amp; Longevity, and Liver Disease, including the following topics: Overview of chronic low-grade inflammation and its impact on disease pathology Updates on Alzheimer\u2019s, Parkinson\u2019s, Epigenetics &amp; Longevity, and Liver Disease clinical programs\u00a0 Clinical and regulatory strategy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-739811","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioVie Announces Registration Details for &quot;BioVie Day&quot; Webinar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVie Announces Registration Details for &quot;BioVie Day&quot; Webinar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) &#8212; BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced registration details for BioVie Day\u2014a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time.\u00a0 BioVie Day will feature a comprehensive overview of the Company\u2019s programs in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Epigenetics &amp; Longevity, and Liver Disease, including the following topics: Overview of chronic low-grade inflammation and its impact on disease pathology Updates on Alzheimer\u2019s, Parkinson\u2019s, Epigenetics &amp; Longevity, and Liver Disease clinical programs\u00a0 Clinical and regulatory strategy &hellip; Continue reading &quot;BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T12:09:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar\",\"datePublished\":\"2023-03-14T12:09:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/\"},\"wordCount\":645,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/\",\"name\":\"BioVie Announces Registration Details for \\\"BioVie Day\\\" Webinar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\",\"datePublished\":\"2023-03-14T12:09:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-announces-registration-details-for-biovie-day-webinar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioVie Announces Registration Details for \"BioVie Day\" Webinar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/","og_locale":"en_US","og_type":"article","og_title":"BioVie Announces Registration Details for \"BioVie Day\" Webinar - Market Newsdesk","og_description":"Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) &#8212; BioVie Inc., (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders\u00a0and advanced liver disease,\u00a0today announced registration details for BioVie Day\u2014a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time.\u00a0 BioVie Day will feature a comprehensive overview of the Company\u2019s programs in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Epigenetics &amp; Longevity, and Liver Disease, including the following topics: Overview of chronic low-grade inflammation and its impact on disease pathology Updates on Alzheimer\u2019s, Parkinson\u2019s, Epigenetics &amp; Longevity, and Liver Disease clinical programs\u00a0 Clinical and regulatory strategy &hellip; Continue reading \"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T12:09:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar","datePublished":"2023-03-14T12:09:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/"},"wordCount":645,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/","name":"BioVie Announces Registration Details for \"BioVie Day\" Webinar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==","datePublished":"2023-03-14T12:09:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NDQyOCM1NDUxMjk4IzUwMDA3OTY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-announces-registration-details-for-biovie-day-webinar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioVie Announces Registration Details for &#8220;BioVie Day&#8221; Webinar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=739811"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739811\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=739811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=739811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=739811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}